These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 12846981)

  • 1. Mitochondria, oxidative damage, and inflammation in Parkinson's disease.
    Beal MF
    Ann N Y Acad Sci; 2003 Jun; 991():120-31. PubMed ID: 12846981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioenergetic approaches for neuroprotection in Parkinson's disease.
    Beal MF
    Ann Neurol; 2003; 53 Suppl 3():S39-47; discussion S47-8. PubMed ID: 12666097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
    Beal MF
    J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease.
    Ogawa O; Zhu X; Perry G; Smith MA
    Sci Aging Knowledge Environ; 2002 Oct; 2002(41):pe16. PubMed ID: 14603007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis.
    Henchcliffe C; Beal MF
    Nat Clin Pract Neurol; 2008 Nov; 4(11):600-9. PubMed ID: 18978800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic role of coenzyme Q(10) in Parkinson's disease.
    Shults CW
    Pharmacol Ther; 2005 Jul; 107(1):120-30. PubMed ID: 15963354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
    Hald A; Lotharius J
    Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease.
    Shults CW; Haas RH; Beal MF
    Biofactors; 1999; 9(2-4):267-72. PubMed ID: 10416040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease.
    Müller T; Büttner T; Gholipour AF; Kuhn W
    Neurosci Lett; 2003 May; 341(3):201-4. PubMed ID: 12697283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive treatments to slow substantia nigra damage and Parkinson's disease progression: A critical perspective review.
    Bjørklund G; Dadar M; Anderson G; Chirumbolo S; Maes M
    Pharmacol Res; 2020 Nov; 161():105065. PubMed ID: 32652199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process.
    Isobe C; Abe T; Terayama Y
    Neurosci Lett; 2010 Jan; 469(1):159-63. PubMed ID: 19944739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
    Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
    Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson's disease.
    Kim H; Kim SH; Cha H; Kim SR; Lee JH; Park JW
    Free Radic Res; 2016 Aug; 50(8):853-60. PubMed ID: 27142242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of mitochondrial dynamics by treadmill training to improve gait and mitochondrial deficiency in a rat model of Parkinson's disease.
    Chuang CS; Chang JC; Cheng FC; Liu KH; Su HL; Liu CS
    Life Sci; 2017 Dec; 191():236-244. PubMed ID: 28986095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotection for Parkinson's disease.
    LeWitt PA
    J Neural Transm Suppl; 2006; (71):113-22. PubMed ID: 17447422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition.
    Kones R
    Nutr Clin Pract; 2010 Aug; 25(4):371-89. PubMed ID: 20702843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coenzyme Q10 in neurodegenerative diseases.
    Shults CW
    Curr Med Chem; 2003 Oct; 10(19):1917-21. PubMed ID: 12871093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.
    Banerjee R; Starkov AA; Beal MF; Thomas B
    Biochim Biophys Acta; 2009 Jul; 1792(7):651-63. PubMed ID: 19059336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.